ArticleAmerican heart journal plus : cardiology research and practice2022
The importance of dosing frequency on the safety of DOACs.
Article in American heart journal plus : cardiology research and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
- Efficacy and safety of reduced-dose versus full-dose DOACs in extended treatment of VTE: A systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants (DOACs) represent a significant advance over vitamin K antagonists, such as warfarin in patients with atrial fibrillation (AF), due to their favorable risk-benefit profile, with significant reductions in stroke and serious bleeding, particularly intracranial hemorrhage.1 Although as class, DOACs tend to reduce major bleeding in general compared to warfarin, they are associated with a significant excess of gastrointestinal (GI) bleeding. A rationale for this observation is that unlike warfarin, the DOACs are active anticoagulants in the gastrointestinal lumen which contributes to GI bleeding above and beyond the systemic exposure to anticoagulant activity. Ido et al. present an interesting study in this issue investigating whether dosing regimen, specifically once vs. twice daily, is the major contributor to a differential GI bleeding profile across the DOACs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.